Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol.

This study was undertaken to assess tolerability, quality of life, and persistency of use and to monitor changes in intraocular pressure (IOP) during the first 6 mo after a switch to fixed combination latanoprost/timolol. In Germany, 271 general ophthalmology practices enrolled patients who were switched from previous ocular hypotensive therapies to latanoprost/timolol for medical reasons. Usual care routines were followed, and IOP was measured at baseline and approximately 6 mo later. Adverse events were recorded throughout. Immediately before switching and at follow-up, patients completed a 29-item quality-of-life questionnaire. Of 1052 patients who met analysis criteria, 748 (71%) switched from combination therapy and 304 (29%) from monotherapy. An insufficient IOP reduction with the previous therapy was a reason for switching in 71% of patients; the desire to simplify to once-daily administration was cited in 66%. Ocular adverse events were reported in 19 patients after the switch, and 97% remained on therapy throughout the follow%up period. After switching, patients were less likely to forget to instill their eyedrops or to feel that their drops had adverse effects; they found it easier to include eyedrop administration in their routine; they were more satisfied with the frequency of instillation; and they were more likely to want to continue with the drops. Across all previous therapies, mean IOP decreased from 20.6+/-3.7 mm Hg to 17.2+/-2.8 mm Hg after the switch (P<.001)-a 14.8% difference. Fixed combination latanoprost/timolol is well tolerated and effective in patients who are switched from other monotherapies or combination therapies for medical reasons. Such a switch may be associated with improved quality of life.

Perioperative risk factors for posterior ischemic optic neuropathy.

BACKGROUND: Infarction of the optic nerve posterior to the lamina cribrosa, called posterior ischemic optic neuropathy (PION), is a condition that can result in profound bilateral blindness. Cases of PION treated at this institution and those described in the literature were analyzed to identify clinical features that profile those individuals at risk of PION in an attempt to identify major contributing factors that could be addressed prophylactically to enable effective prevention. STUDY DESIGN: Salient clinical features in seven cases of PION diagnosed at the Doheny Eye Institute between 1989 and 1998 are compared with 46 cases of PION reported in the literature. RESULTS: In the Doheny series there were six men and one woman aged 12 to 66 years (mean, 47 years). Five patients were status-post spine surgery, one was status-post knee surgery, and one had a bleeding stomach ulcer. Vision loss was simultaneously bilateral in six of seven patients (85.7%) and was apparent immediately after surgery. There were no abnormal retinal or choroidal findings including diabetic retinopathy, in any of the patients. Notable contributing factors were blood loss in all seven patients, ranging from 2,000 to 16,000 mL, with a drop in hematocrit of 9.5% to 19% (mean, 14%), and intraoperative systemic hypotension in all patients. Facial edema was a factor in three of six spine surgery patients (50%). Patients reported in the literature had a mean age of 50 years and were also predominantly men (34 of 46, 74%) who underwent spine surgery (30 of 46, 65.2%). CONCLUSIONS: Middle-aged men undergoing spine surgery with prolonged intraoperative hypotension and postoperative anemia and facial swelling are at risk of developing PION from hypovolemic hypotension. Avoiding or immediately correcting these contributory factors can reduce the incidence of PION.